Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia

St. Jude Children’s Research Hospital scientists have improved chimeric antigen receptor (CAR) T–cell immunotherapy for acute myeloid leukemia (AML), demonstrating better efficacy in the lab.

Leave A Comment

Your email address will not be published. Required fields are marked *